home

BeiGene Presents Clinical Data for RAF Dimer Inhibitor BGB-283 at the 2016 American Association for Cancer Research Annual Meeting

TrendBeiGene2016-04-20 15:37 Read   95

BeiGene, Ltd. (NASDAQ:BGNE) (“BeiGene”), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the presentation of initial clinical data from an ongoing Phase I clinical trial of BGB-283 in patients with BRAF or KRAS/NRAS-mutated cancers in the Clinical Trials Plenary Session at the 2016 American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA.

Sanofi expands biologics plant, adding 100 workers

Trendfiercepharma2016-04-20 13:26 Read   67

Sanofi ($SNY) turned to Boehringer Ingelheim last year to get the added manufacturing capacity it figured it would need for a host of new monoclonal antibodies (mAbs) it was developing with partner Regeneron ($REGN).

AB Science claims a positive result in masitinib ALS study

Trendepvantage2016-04-20 10:45 Read   116

France’s AB Science seems to have notched up an unexpected positive interim readout in a phase III study with its c-KIT inhibitor, masitinib, in the difficult indication of amyotrophic lateral sclerosis (ALS).

Bristol-Myers Squibb's PD-1 inhibitor Opdivo prolongs survival in head and neck cancer: study

TrendFIRSTWORD2016-04-20 10:20 Read   90

Study data presented Tuesday at the American Association for Cancer Research (AACR) annual meeting showed that Bristol-Myers Squibb's Opdivo (nivolumab) conferred a survival benefit in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum therapy, compared with three standard of care options.

Sucampo Reports Top-Line Data from Phase 2a Study of Cobiprostone in Patients with PPI-Refractory Non-Erosive Reflux Disease (NERD) and Symptomatic Gastroesophageal Reflux Disease (sGERD)

TrendYAHOO2016-04-20 09:49 Read   100

Sucampo Pharmaceuticals, Inc. (Sucampo) (SCMP), a global biopharmaceutical company, today announced top-line data from a Phase 2a study of cobiprostone in patients with proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD) or symptomatic gastroesophageal reflux disease (sGERD).  

Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL)

TrendMerck2016-04-19 16:22 Read   285

Fourth Designation for KEYTRUDA Follows Breakthrough Status in Advanced Melanoma, Non-Small Cell Lung Cancer, and Colorectal Cancer

First Presentation of Two-Year Overall Survival Data for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) Showed Superior Efficacy Versus Yervoy Alone in Advanced Melanoma

TrendBristol-Myers Squibb Company2016-04-19 11:36 Read   67

Bristol-Myers Squibb Company (NYSE:BMY) announced today first time presentation of overall survival data from CheckMate -069, a Phase 2 trial and the first randomized study to evaluate the Opdivo and Yervoy combination regimen in patients with previously untreated advanced melanoma.

Nationwide Reveals the 10 Most Common Medical Conditions for Dogs and Cats

TrendNationwide2016-04-19 11:05 Read   83

Nation's Largest Pet Insurer Unveils Top Pet Ailments that Prompt Veterinary Visits

Transition Therapeutics Provides Update on Type 2 Diabetes Drug Candidate TT401

TrendTransition Therapeutics2016-04-19 10:38 Read   63

Transition Therapeutics Inc. today announced that it has received notification that Eli Lilly and Co.(“Lilly”) will not elect to advance diabetes drug candidate, TT401 into Phase 3 development.

AbbVie Presents New Phase 2 Data for Investigational, Once-Daily, Ribavirin-Free, Pan-Genotypic Regimen of ABT-493 and ABT-530 for Hepatitis C Genotypes 1-6

Trendabbvie2016-04-19 10:26 Read   72

AbbVie today announced that with eight weeks of treatment, 97-98 percent of genotype 1-3 (GT1-3) chronic hepatitis C virus (HCV) infected patients without cirrhosis treated with AbbVie's investigational, once-daily, ribavirin (RBV)-free, pan-genotypic regimen of ABT-493 and ABT-530 achieved sustained virologic response at 12 weeks post-treatment (SVR12).

Loxo Oncology TRK Inhibitor LOXO-101 Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers in AACR Phase 1 Update

Trendloxooncology2016-04-19 10:14 Read   62

Loxo Oncology, Inc. (Nasdaq:LOXO), today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK).

Upcoming events – Phase II data for Raptor and The Medicines Company

Trendepvantage2016-04-18 14:20 Read   58

Welcome to your weekly digest of approaching regulatory and clinical readouts. Raptor Pharmaceutical’s efforts to expand the reach of Procysbi are approaching another milestone with the release this quarter of interim data from a phase II/III study in inherited mitochondrial diseases.